BFRI
Biofrontera Inc. [BFRI] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
BFRI Stock Summary
Top 10 Correlated Stocks
BFRI
In the News
BFRI Financial details
Company Rating
-
Market Cap
10.64M
Income
-20.13M
Revenue
34.06M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
83
Optionable
No
Shortable
Yes
Earnings
12 May 2024
P/E
-0.13
Forward P/E
-
PEG
-0
P/S
0.11
P/B
3.23
P/C
-
P/FCF
-0.15
Quick Ratio
0.46
Current Ratio
1.02
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-15.82
EPS next Y
-
EPS next Q
-
EPS this Y
2034.43%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-6.37%
Revenue last 5Y
5.41%
Revenue Q/Q
19.34%
EPS Q/Q
-135.56%
-
-
-
-
SMA20
6.17%
SMA50
21.13%
SMA100
-12.24%
Inst Own
-
Inst Trans
-
ROA
-78%
ROE
-217%
ROC
-4.89%
Gross Margin
49%
Oper. Margin
-72%
Profit Margin
-79%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.61-13.42
52W High
-
52W Low
-
RSI
50.7
Rel Volume
0.07
Avg Volume
802.19K
Volume
52.29K
Perf Week
-2.96%
Perf Month
-11.81%
Perf Quarter
-3.38%
Perf Half Y
3.98%
-
-
-
-
Beta
0.838
-
-
Volatility
0.02%, 0.05%
Prev Close
-0.05%
Price
0.8696
Change
2.79%
Company Profile
- Volume Average 802.19K
- Market Capitalization 10.64M
- Employee 83
- CEO Dr. Hermann Luebbert Ph.D.
- Headquarters Woburn,MA,US
- IPO Date 2021-10-29
-
Website
https://www.biofrontera.us.com 
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, which is a prescription drug approved for use in combination with the company's licensor's medical device; and the RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also Xepi, a prescription cream for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
